Markets:

Overview

News

Currencies

International

Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

20.43 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 15, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

uniQure Stock Tumbled 56% Today: What’s The FDA Angle? ↗

November 03, 2025

Via Stocktwits

Gapping stocks in Monday's session ↗

November 03, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE

November 03, 2025

From The DJS Law Group

Via Business Wire

Nasdaq Surges 1%; ON Semiconductor Posts Upbeat Q3 Earnings ↗

November 03, 2025

Via Benzinga

Uniqure Plummets 59% On A 'Confusing' And 'Unexpected' Twist For Its Gene Therapy ↗

November 03, 2025

An analyst described the FDA feedback as "confusing" and "unexpected" for the experimental Huntington's disease treatment.

Via Investor's Business Daily

Discover the top movers in Monday's pre-market session. ↗

November 03, 2025

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 03, 2025

Via Benzinga

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

November 03, 2025

From uniQure Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

October 30, 2025

Via Benzinga

Breakout Momentum Plays You Need to Know About ↗

October 23, 2025

Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential.

Via MarketBeat

Why Is Protalix BioTherapeutics Stock Falling On Friday? ↗

October 17, 2025

EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy.

Via Benzinga

Cramer Warns On One Chip Stock, Says Broadcom Is The Better Bet ↗

October 06, 2025

Jim Cramer recommends caution with Ambiq Micro (AMBQ) and suggests Broadcom (AVGO). He dislikes Albertsons (ACI) and advises selling some Dillard's (DDS).

Via Benzinga

QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop ↗

October 03, 2025

Biotech stock uniQure just popped nearly 250% in one day, with an analyst calling its trial results "amazing". Wall Street sees significant upside to come.

Via MarketBeat

10 Health Care Stocks Whale Activity In Today's Session ↗

October 01, 2025

Via Benzinga

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

September 29, 2025

From uniQure Inc.

Via GlobeNewswire

Benzinga Bulls And Bears: Oracle, Costco, NIO — And Wall Street Snaps Its Slide ↗

September 27, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

uniQure Announces Pricing of Upsized $300 Million Public Offering

September 25, 2025

From uniQure Inc.

Via GlobeNewswire

UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street ↗

September 25, 2025

UniQure NV (NASDAQ: QURE) just staged one of biotech's wildest rides of the year, soaring 248% in a single session after unveiling successful trial results for its experimental Huntington's disease...

Via Benzinga

CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗

September 25, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

uniQure Stock Jumps On Positive News, But Risks Remain ↗

September 25, 2025

uniQure (NASDAQ: QURE) has been one of the most eye-catching movers in recent sessions. The stock surged ~250% this Wednesday after reports that the company's gene therapy showed positive results in...

Via Benzinga

Wall Street Pauses AI Frenzy as Oracle Seeks $15B in Fresh Funding ↗

September 25, 2025

After weeks of record highs fueled by AI optimism, U.S. stocks cooled for a second straight day. Oracle’s massive debt raise and divergent moves in chipmakers set the tone, while housing and lithium...

Via Chartmill

Topics Artificial Intelligence

Alibaba, Intel, Uniqure, Tesla And Opendoor: Why These 5 Stocks Are On Investors' Radars Today ↗

September 24, 2025

U.S. stocks slipped on Wednesday, with the Nasdaq losing more than 75 points, or 0.3%, to close at 22,497.85.

Via Benzinga

UniQure Stock Hits 5-Year High As Analysts Hail Huntington’s Therapy Data — Retail Spots ‘Diamond In Rough Of Biotech’ ↗

September 24, 2025

UniQure said the high-dose of its AMT-130 therapy slowed Huntington’s disease progression by up to 75% over three years and plans to seek FDA approval in early 2026.

Via Stocktwits

uniQure Announces $200 Million Proposed Public Offering

September 24, 2025

From uniQure Inc.

Via GlobeNewswire

Nasdaq Down Over 100 Points; US Crude Oil Stocks Fall ↗

September 24, 2025

Via Benzinga

What's Going On With UniQure Stock Wednesday? ↗

September 24, 2025

UniQure N.V. (NASDAQ:QURE) shares are trading higher Wednesday after the company announced positive topline results from Phase I/II study of AMT-130 in patients with Huntington's Disease.

Via Benzinga

Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today ↗

September 24, 2025

Via Stocktwits

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 24, 2025

Via Benzinga

A Cure For Huntington's Disease? UniQure Launches More Than 240%. ↗

September 24, 2025

The company's gene therapy slowed disease progression by 75% over three years.

Via Investor's Business Daily

uniQure Stock Doubles On Promising Data From Huntington's Disease Trial ↗

September 24, 2025

UniQure's AMT-130 gene therapy slowed Huntington's disease progression in a Phase 1/2 trial, supported by new $175 million financing for launch readiness.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

uniQure N.V. - Ordinary Shares (NQ:QURE)

All News about uniQure N.V. - Ordinary Shares

Starting at $3.75/week.

Subscribe Today